|By PR Newswire||
|August 1, 2014 05:05 PM EDT||
SOUTH PLAINFIELD, N.J., Aug. 1, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on July 31, 2014 it approved non-statutory stock options to purchase an aggregate of 67,700 shares of its common stock to seven new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.
The inducement grants were approved by PTC's Compensation Committee on July 31, 2014 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
Five of the stock option awards have an exercise price of $26.42 per share, the closing price of PTC's common stock on July 31, 2014. The remaining stock option awards have an exercise price of $27.74 per share, the closing price of the PTC stock on August 1, 2014. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and an additional 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter, subject to the employee's continued service with the Company through the applicable vesting dates.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and in collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com.
SOURCE PTC Therapeutics, Inc.
Jan. 18, 2017 05:00 PM EST Reads: 1,102
Jan. 18, 2017 05:00 PM EST
Jan. 18, 2017 04:45 PM EST Reads: 4,867
Jan. 18, 2017 04:45 PM EST Reads: 5,359
Jan. 18, 2017 04:45 PM EST Reads: 4,501
Jan. 18, 2017 04:30 PM EST Reads: 4,615
Jan. 18, 2017 03:45 PM EST Reads: 4,662
Jan. 18, 2017 03:30 PM EST Reads: 3,666
Jan. 18, 2017 03:30 PM EST Reads: 3,398
Jan. 18, 2017 02:45 PM EST Reads: 1,585
Jan. 18, 2017 02:15 PM EST Reads: 972
Jan. 18, 2017 02:00 PM EST Reads: 373
Jan. 18, 2017 02:00 PM EST Reads: 919
"There's a growing demand from users for things to be faster. When you think about all the transactions or interactions users will have with your product and everything that is between those transactions and interactions - what drives us at Catchpoint Systems is the idea to measure that and to analyze it," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York Ci...
Jan. 18, 2017 01:00 PM EST Reads: 5,592
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Jan. 18, 2017 01:00 PM EST Reads: 5,097